Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Kasama-shi、日本、3091793
- Local Institution
-
-
Aichi
-
Nagoya-shi、Aichi、日本、4600001
- Local Institution
-
Nagoya-shi、Aichi、日本、4678602
- Local Institution
-
-
Aomori
-
Aomori-shi、Aomori、日本、0308553
- Local Institution
-
-
Chiba
-
Chiba-shi、Chiba、日本、2608677
- Local Institution
-
Kamogawa-shi、Chiba、日本、2968602
- Local Institution
-
-
Ehime
-
Matsuyama-shi、Ehime、日本、7900024
- Local Institution
-
-
Fukuoka
-
Fukuoka-shi、Fukuoka、日本、8128582
- Local Institution
-
-
Gunma
-
Maebashi-shi、Gunma、日本、3718511
- Local Institution
-
Shibukawa-shi、Gunma、日本、3770280
- Local Institution
-
-
Hiroshima
-
Fukuyama-shi、Hiroshima、日本、7200001
- Local Institution
-
-
Iwate
-
Morioka-shi、Iwate、日本、0208505
- Local Institution
-
-
Kagoshima
-
Kagoshima-shi、Kagoshima、日本、8920853
- Local Institution
-
-
Kyoto
-
Kyoto-shi、Kyoto、日本、6028566
- Local Institution
-
-
Miyagi
-
Sendai、Miyagi、日本、9808574
- Local Institution
-
-
Niigata
-
Niigata-shi、Niigata、日本、9518566
- Local Institution
-
-
Okayama
-
Okayama-shi、Okayama、日本、7011192
- Local Institution
-
-
Osaka
-
Osaka-shi、Osaka、日本、5438555
- Local Institution
-
Osaka-shi、Osaka、日本、5300012
- Local Institution
-
-
Saitama
-
Kawagoe-shi、Saitama、日本、3508550
- Local Institution
-
-
Shizuoka
-
Hamamatsu-shi、Shizuoka、日本、4313192
- Local Institution
-
-
Tochigi
-
Utsunomiya-shi、Tochigi、日本、3200834
- Local Institution
-
-
Tokyo
-
Bunkyo-ku、Tokyo、日本、1138677
- Local Institution
-
Koto-ku、Tokyo、日本、1358550
- Local Institution
-
Shibuya-ku、Tokyo、日本、1508935
- Local Institution
-
Shinjuku-Ku、Tokyo、日本、1608582
- Local Institution
-
Shinjuku-ku、Tokyo、日本、1628655
- Local Institution
-
Tachikawa-shi、Tokyo、日本、1900014
- Local Institution
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Newly diagnosed with symptomatic Multiple Myeloma (MM)
- Have not received any prior systemic anti-myeloma therapy
- Have measurable disease
- Are not candidates for high-dose therapy plus stem-cell transplantation (SCT) because of age (≥ 65 years) or coexisting conditions. Refusal to undergo high dose therapy with SCT is NOT sufficient for entry onto CA204-116 for a subject < 65 years old. There must be a comorbidity that prevents SCT for a subject < 65 years old
Exclusion Criteria:
- Non-secretory myeloma
- Smoldering MM, defined as asymptomatic MM with absence of lytic bone lesions
- Monoclonal Gammopathy of Undetermined Significance (MGUS)
- Active plasma cell leukemia
- Known Human Immunodeficiency Virus (HIV) infection or active hepatitis A, B, or C
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Arm A: Lenalidomide + Dexamethasone + Elotuzumab (BMS-901608)
Drug: Lenalidomide Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug Drug: Dexamethasone Tablets, Oral 28 mg and Intravenous (IV) 8 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug Biological: Elotuzumab (BMS-901608) Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug |
|
|
有源比较器:Arm B: Lenalidomide + Dexamethasone
Drug: Lenalidomide Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug Drug: Dexamethasone Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld)
大体时间:From first dose until documented response (assessed up to February 2017, approximately 24 months)
|
ORR is the proportion of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or PR as determined by investigator using the International Myeloma Working Group (IMWG) response criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. |
From first dose until documented response (assessed up to February 2017, approximately 24 months)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Objective Response Rate (ORR)
大体时间:From first dose until documented response, up to approximately 72 months
|
ORR is the percentage of randomized participants who achieve a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) as determined by investigator using the International Myeloma Working Group (IMWG) response criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. |
From first dose until documented response, up to approximately 72 months
|
|
Progression Free Survival (PFS)
大体时间:From randomization to the date of first documented tumor progression or death due to any cause, up to approximately 72 months
|
PFS is defined as the time from randomization to the date of the first documented tumor progression, as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria, or to death due to any cause, provided death does not occur more than 10 weeks (2 or more assessment visits) after the last tumor assessment.
Clinical deterioration will not be considered progression.
|
From randomization to the date of first documented tumor progression or death due to any cause, up to approximately 72 months
|
|
Progression Free Survival (PFS) Rate
大体时间:From randomization up to the specified timepoints, up to 3 years
|
PFS rate is defined as the percentage of participants who have neither progressed nor died at the specified timepoints
|
From randomization up to the specified timepoints, up to 3 years
|
合作者和调查者
合作者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- CA204-116
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.